Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.

导出 LinkOut

翻译打印收藏纠错

第一作者： Deshan,Yuan

第一单位： National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, PR China.

作者： Deshan,Yuan ^[1] ; Peizhi,Wang ^[1] ; Sida,Jia ^[1] ; Ce,Zhang ^[1] ; Pei,Zhu ^[1] ; Lin,Jiang ^[1] ; Ru,Liu ^[1] ; Jingjing,Xu ^[1] ; Xiaofang,Tang ^[1] ; Ying,Song ^[1] ; Yi,Yao ^[1] ; Na,Xu ^[1] ; Yin,Zhang ^[1] ; Xueyan,Zhao ^[1] ; Yuejin,Yang ^[1] ; Bo,Xu ^[1] ; Lijian,Gao ^[1] ; Zhan,Gao ^[1] ; Runlin,Gao ^[2] ; Jinqing,Yuan ^[3]

作者单位： National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, PR China. ^[1] National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, PR China. Electronic address: gaorunlin@citmd.com. ^[2] National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, PR China. Electronic address: dr_jinqingyuan@sina.com. ^[3]

关键词 Coronary artery disease Lipoprotein(a)Percutaneous coronary intervention hsCRP